DadFinStart your free week
DadFin › Stocks › Healthcare › TAK

Takeda Pharmaceutical Company Limi (TAK) stock score

Healthcare · Drug Manufacturers - Specialty & Generic · Japan

$18.73 ▲ +1.13% today

32.9
Dad Score, out of 100
weak

Takeda Pharmaceutical Company Limi (TAK) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, listed in Japan. On DadFin's weekly run it scores 32.9 out of 100 on the Dad Score, a weak reading that places the business ahead of 33% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #604 of 974. Its strongest axes are valuation, quality and liquidity; its weakest are growth and price action.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Above average
Quality
Above average
Growth
Weak
Price action
Below average
Risk
Weak
Conviction
Weak
Liquidity
Above average
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)0.0×
P/E (forward)33.7×
Dividend yield3.45%
Return on capital0.0%
Operating margin16.5%
Revenue growth (YoY)-1.7%
FCF yield14.4%
Net debt / EBITDA4.06×
Piotroski F-Score4 / 9
52-week change+22.8%
Market cap$57.1B
Next earningsOct 29, 2026

What subscribers see on TAK

Start your free weekSubscriber? Open the full research →

Drug Manufacturers - Specialty & Generic peers

StockCompanyDad ScoreBandMarket cap
TEVATeva Pharmaceutical Industries Lim93.6strong$46.1B
HLNHaleon plc64.5middling$38.7B
ZTSZoetis Inc.61.2middling$28.8B
UTHRUnited Therapeutics Corporation99.8strong$23.2B
VTRSViatris Inc.54.4middling$20.2B
NBIXNeurocrine Biosciences, Inc.98.4strong$14.6B
ELANElanco Animal Health Incorporated84.0good$11.1B
RDYDr. Reddy's Laboratories Limited28.5weak$10.2B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.